U.S stocks ended Friday trading sharply higher and investors cheered positive information about the corona virus treatment from Gilead Science. The Dow Jones Industrial Average gained 369.21 points, or 1.44% to close at 26,075.30. The S&P 500 climbed 1.05% to 3,185.04 and the tech-heavy Nasdaq Composite Index advanced 0.66% to 10,617.44. Reducing their losses for this period as the distribution of the coronavirus pandemic continued to threaten the recovery in the economy.

Contributors of Gilead Sciences Inc. earned 2.0% at premarket trading on Friday after the drug maker revealed findings from the recent investigations of previously revealed clinical test information that discovered the research therapy Remdesivir can reduce the risk of mortality  in corona virus patients by 62% compared with current standard care. Gilead said that mortality data end is “an important discovery that involves proof in future clinical trials.” Gilead’s stock price was already up since news that its antiviral drug Remdesivir, which was created to treat Ebola, was being given to Covid-19 patients.

Total U.S. cases of coronavirus climbed to more than 3.1 million and the death toll topped 133,000, according to data compiled by Johns Hopkins University. Gilead is working closely with international health agencies to react to the new coronavirus outbreak through  research of usage of the investigational substance Remdesivir. Gilead is focused on contributing their antiviral expertise and resources to help patients and communities fighting coronavirus (COVID-19).